Kentaro Tajima

Current Situation and Challenges Regarding Biosimilars In Japan: An Example Of Trastuzumab Biosimilars For Breast Cancer

Fumikata Hara, Kentaro Tajima, Kosuke Tanabe · Future Oncology · 2019 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study

Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori et al. · Breast Cancer · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

Validity of Administrative Data for Identifying Birth-Related Outcomes with the End Date of Pregnancy in a Japanese University Hospital

Kentaro Tajima, Tomofumi Ishikawa, Fumiko Matsuzaki et al. · International Journal of Environmental Research and Public Health · 2022 · 13 citations · Full text

Public Health, Maternal Health, Obstetrics +15

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk et al. · BioDrugs · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16